IdJMR Interdisciplinary Journal of Medical Research
Therapy Plus Clinics

Original Article

Prevalence of Chemotherapy-Associated Acute Kidney Injury in Children with Solid Versus Non-Solid Tumors at a Tertiary Pediatric Center

Fariha Tariq [1]

1. University of Lahore, Lahore, Pakistan

* Correspondence: **farihatariq064@gmail.com**

Received: 12 October 2024 | Revised: 17 November 2024 | Accepted: 15 December 2024 | Published: 30 December 2024

Citation: Click to Cite | Copyright: © 2024 The Authors. | Publisher: Therapy Plus Clinics (TPC), Pakistan.

ABSTRACT

***Background**: Chemotherapy-associated acute kidney injury (AKI) is a significant complication in pediatric oncology, yet variation in AKI burden between children with solid and non-solid tumors remains insufficiently characterized. Understanding tumor-specific differences in renal vulnerability is essential for improving monitoring strategies and mitigating treatment-related morbidity. **Objective**: To determine the prevalence of chemotherapy-associated AKI in children with solid versus non-solid tumors treated at a tertiary pediatric center and to identify clinical factors associated with increased renal risk. **Methods**: A cross-sectional observational study was conducted among 60 pediatric oncology patients, with equal representation of solid and non-solid tumors. Demographic, clinical, and chemotherapy-related variables were collected through standardized chart review. AKI was defined using KDIGO pediatric serum creatinine criteria. Statistical analyses included group comparisons and multivariable logistic regression to identify predictors of AKI while adjusting for confounders. **Results**: AKI occurred in 35.0% of the cohort, with higher prevalence among solid tumor patients (43.3%) compared with those with non-solid tumors (26.7%). Solid tumor patients exhibited greater rises in peak serum creatinine (0.98 vs. 0.82 mg/dL). Nephrotoxic chemotherapy exposure (adjusted OR 3.41) and dehydration (adjusted OR 2.77) were significant predictors of AKI. **Conclusion**: Children with solid tumors experience a higher burden of chemotherapy-associated AKI, driven primarily by nephrotoxic drug exposure and modifiable clinical factors. Enhanced renal surveillance and preventive measures are warranted in high-risk groups.*

***Keywords**: Acute Kidney Injury; Chemotherapy; Pediatric Oncology; Solid Tumors; Nephrotoxicity; KDIGO Criteria*

INTRODUCTION

Acute kidney injury (AKI) is a clinically significant complication in pediatric oncology, arising both from the direct nephrotoxic effects of chemotherapeutic agents and from tumor-related factors such as metabolic derangements, sepsis, and hemodynamic instability (1). Children with cancer represent a uniquely vulnerable population due to developmental renal physiology, increased susceptibility to nephrotoxicity, and the cumulative burden of multimodal treatment regimens (2). Although the incidence of chemotherapy-associated AKI has been well documented in adults, pediatric data remain limited and heterogeneous, with reported prevalence varying widely depending on tumor type, chemotherapy protocol, diagnostic criteria, and clinical setting (3). Evidence suggests that children with solid tumors may experience different patterns of renal injury compared with those with hematologic malignancies, owing to variations in tumor biology, baseline renal perfusion, and exposure to nephrotoxic agents such as platinum-based compounds, ifosfamide, and high-dose methotrexate (4). Conversely, children with non-solid tumors, particularly leukemias and lymphomas, may also encounter substantial renal risk due to tumor lysis syndrome, cytokine-mediated inflammation, and the intensity of induction chemotherapy (5).

Despite the recognized importance of AKI in pediatric oncology, the comparative burden of chemotherapy-associated AKI between solid and non-solid tumor groups remains understudied, particularly in low- and middle-income contexts where resource limitations may affect early detection, supportive care, and treatment modifications (6). A clearer understanding of tumor-specific differences in AKI prevalence is essential for refining nephroprotective strategies, guiding surveillance protocols, and informing clinicians about risk-adaptive chemotherapy planning. Existing studies are constrained by small sample sizes, inconsistent AKI definitions, and limited comparative analyses, resulting in uncertainty regarding which pediatric oncology subgroups are at greatest renal risk (7). This knowledge gap has direct clinical implications because timely identification of AKI can prevent progression to chronic kidney disease, reduce treatment interruptions, and ultimately improve survival outcomes (8).

Using a PICO-oriented conceptual framework, the population of interest comprises children undergoing chemotherapy for either solid or non-solid tumors; the exposure relates to tumor category and associated

chemotherapy regimens; the comparator involves differences in AKI prevalence between these groups; and the outcome is the occurrence of chemotherapy-associated AKI as defined by standardized pediatric criteria. Addressing this gap is critical for developing targeted renal monitoring approaches and optimizing supportive care interventions across tumor types. Accordingly, the present study aims to determine the prevalence of chemotherapy-associated AKI in pediatric patients with solid tumors compared with those with non-solid tumors, with the objective of identifying differential risk patterns that may inform clinical practice and future research. The study seeks to answer the following research question: Does the prevalence of chemotherapy-associated acute kidney injury differ between children with solid tumors and those with non-solid tumors receiving treatment at a tertiary pediatric center?

MATERIAL AND METHODS

The study employed a cross-sectional observational design to estimate and compare the prevalence of chemotherapy-associated acute kidney injury (AKI) in children with solid and non-solid tumors, a design appropriate for capturing outcome frequency and exposure–outcome associations within a defined population without introducing treatment-related bias (9). The investigation was conducted at the Children's Medical Center, a tertiary pediatric referral hospital with specialized oncology services, where all eligible patients admitted for chemotherapy during the study period were consecutively screened to minimize selection bias. Eligible participants included children aged 1 month to 18 years who had a confirmed diagnosis of either a solid tumor or a non-solid tumor and were actively receiving chemotherapy. Exclusion criteria comprised pre-existing chronic kidney disease, congenital renal anomalies, prior renal replacement therapy, or incomplete laboratory or clinical records. Eligible families were approached for informed consent in accordance with institutional ethical procedures, and assent was obtained from age-appropriate children.

Data collection was performed using a structured extraction protocol applied to electronic medical records, chemotherapy logs, and laboratory information systems. Trained research personnel obtained demographic information, tumor type, chemotherapy regimen, dosing cycles, baseline renal function, concomitant nephrotoxic medications, and relevant clinical events. Serum creatinine values were collected before chemotherapy initiation and at scheduled intervals during treatment, enabling AKI classification based on Kidney Disease: Improving Global Outcomes (KDIGO) pediatric criteria, which define AKI by an increase in serum creatinine ≥1.5 times baseline within seven days (10). AKI was coded as a binary outcome, while tumor type served as the primary exposure variable. Additional variables included age, sex, hydration status, chemotherapy class (including nephrotoxic agents such as cisplatin, carboplatin, ifosfamide, and high-dose methotrexate), and comorbidities known to influence renal vulnerability. Ten percent of extracted data were independently verified by a secondary reviewer to ensure accuracy and reproducibility.

Potential confounding was addressed by prespecifying biologically relevant covariates associated with both tumor category and AKI risk—such as baseline renal function, exposure to nephrotoxic drugs, and chemotherapy intensity—which were adjusted for in multivariable models (11). Consecutive sampling and standardized AKI definitions reduced selection and information biases, while exclusion of children with pre-existing renal disease minimized misclassification. The sample size of 60 patients was selected to provide at least 80% power to detect a clinically meaningful difference in AKI prevalence between tumor groups, assuming an expected prevalence difference of 20% based on prior pediatric oncology studies, with $\alpha = 0.05$ (12).

Statistical analysis was performed using Stata and R software. Descriptive statistics were used to summarize baseline characteristics, with continuous variables expressed as means and standard deviations or medians and interquartile ranges depending on distribution. Categorical variables were presented as frequencies and percentages. Associations between tumor type and AKI were examined using chi-square tests for proportions and t-tests or Mann–Whitney U tests for continuous variables. Multivariable logistic regression was used to estimate adjusted odds ratios for AKI, incorporating confounders identified a priori. Missing data were evaluated for mechanism and proportion; complete-case analysis was applied when missingness was below 5%, whereas multiple imputation was considered for higher but random missingness patterns. Subgroup analyses were planned to compare AKI risk by specific chemotherapy classes and age categories to explore potential effect modification. Ethical approval was obtained from the institutional review board, and all procedures adhered to the Declaration of Helsinki. Participant confidentiality was maintained through assignment of coded identifiers and secure storage of data in encrypted repositories. To ensure reproducibility, all analytic procedures, variable definitions, and statistical code were documented in a version-controlled protocol accessible to the study team.

RESULTS

The study included 60 children receiving chemotherapy, evenly divided between solid tumors (n = 30) and non-solid tumors (n = 30). Baseline characteristics (Table 1) showed that the overall mean age was 8.4 ± 4.1 years, with children in the solid tumor group slightly older (9.1 ± 4.3 years) than those with non-solid tumors (7.8 ± 3.9 years). Males constituted 55% of the sample, with comparable distributions across tumor categories. Baseline

renal function was preserved in both groups, with mean serum creatinine values of 0.52 ± 0.12 mg/dL for solid tumors and 0.48 ± 0.11 mg/dL for non-solid tumors. Dehydration at admission was present in 20% of children, most commonly among those with solid tumors (23.3%). Exposure to nephrotoxic agents—such as cisplatin, carboplatin, or ifosfamide—occurred in 70% of children with solid tumors compared with 46.7% in the non-solid tumor group, reflecting substantial differences in chemotherapy profiles.

Chemotherapy characteristics and renal biomarkers (Table 2) demonstrated clinically meaningful contrasts between groups. Cisplatin-based regimens were administered far more frequently in solid tumors (40.0%) than in non-solid tumors (6.7%, p = 0.004), whereas high-dose methotrexate exposure was significantly more common in non-solid tumors (46.7% vs. 10.0%, p = 0.002). Ifosfamide exposure occurred in 26.7% of solid tumor patients versus 10.0% of non-solid tumor patients. Although cumulative chemotherapy cycles were similar between groups, peak serum creatinine values were higher among children with solid tumors (0.98 ± 0.24 mg/dL) compared with those with non-solid tumors (0.82 ± 0.20 mg/dL, p = 0.01).

Table 1. Baseline Characteristics of the Study Cohort (n = 60)

Variable	Solid Tumors (n = 30)	Non-Solid Tumors (n = 30)	Total (n = 60)
Age (years), mean ± SD	9.1 ± 4.3	7.8 ± 3.9	8.4 ± 4.1
Male sex, n (%)	17 (56.7%)	16 (53.3%)	33 (55.0%)
Baseline serum creatinine (mg/dL), mean ± SD	0.52 ± 0.12	0.48 ± 0.11	0.50 ± 0.12
Dehydration at admission, n (%)	7 (23.3%)	5 (16.7%)	12 (20.0%)
Exposure to nephrotoxic drugs*, n (%)	21 (70.0%)	14 (46.7%)	35 (58.3%)
Intensive chemotherapy protocol, n (%)	18 (60.0%)	20 (66.7%)	38 (63.3%)

Table 2. Chemotherapy Characteristics and Renal Biomarkers

Variable	Solid Tumors (n = 30)	Non-Solid Tumors (n = 30)	p-value
Cisplatin-based regimen, n (%)	12 (40.0%)	2 (6.7%)	0.004
Ifosfamide exposure, n (%)	8 (26.7%)	3 (10.0%)	0.10
High-dose methotrexate, n (%)	3 (10.0%)	14 (46.7%)	0.002
Mean cumulative chemotherapy cycles completed	3.1 ± 1.4	3.4 ± 1.2	0.42
Peak serum creatinine during treatment (mg/dL)	0.98 ± 0.24	0.82 ± 0.20	0.01
Median creatinine rise from baseline (%)	72% (IQR 45–118)	51% (IQR 30–76)	—

Table 3. Prevalence and Severity of Chemotherapy-Associated AKI

Outcome	Solid Tumors (n = 30)	Non-Solid Tumors (n = 30)	Total (n = 60)	p-value
AKI (KDIGO-defined), n (%)	13 (43.3%)	8 (26.7%)	21 (35.0%)	0.16
AKI Stage 1, n (%)	6 (20.0%)	5 (16.7%)	11 (18.3%)	—
AKI Stage 2, n (%)	4 (13.3%)	2 (6.7%)	6 (10.0%)	—
AKI Stage 3, n (%)	3 (10.0%)	1 (3.3%)	4 (6.7%)	—
Need for temporary dialysis, n (%)	1 (3.3%)	0 (0.0%)	1 (1.7%)	—
Time to AKI onset (days post-chemotherapy), mean ± SD	4.6 ± 1.8	5.1 ± 2.2	4.8 ± 2.0	0.40

Table 4. Logistic Regression: Predictors of AKI (n = 60)

Predictor Variable	Adjusted OR	95% CI	p-value
Solid tumor (vs. non-solid)	1.92	0.73–4.98	0.18
Exposure to nephrotoxic chemotherapy	3.41	1.21–9.58	0.02
Dehydration at admission	2.77	1.01–7.63	0.048
Intensive chemotherapy protocol	1.36	0.54–3.39	0.51
Age (per 1-year increase)	0.94	0.85–1.05	0.28

The median creatinine rise from baseline also differed, increasing by 72% (IQR 45–118) in solid tumors compared with 51% (IQR 30–76) in non-solid tumors.

The prevalence and severity of chemotherapy-associated AKI (Table 3) revealed that 21 of 60 children (35.0%) developed AKI based on KDIGO criteria. AKI occurred more frequently in solid tumors (43.3%) than in non-solid tumors (26.7%), although this difference did not reach statistical significance (p = 0.16). Stage 1 AKI accounted for 18.3% of cases overall, while more severe forms—Stage 2 and Stage 3—occurred in 10.0% and 6.7% of the cohort, respectively. Severe AKI requiring temporary dialysis was rare, observed in only one child

(3.3%) within the solid tumor group. The mean time to AKI onset was similar between groups, averaging 4.6 ± 1.8 days for solid tumors and 5.1 ± 2.2 days for non-solid tumors.

Multivariable logistic regression (Table 4) identified specific predictors of AKI independent of tumor type. Exposure to nephrotoxic chemotherapy significantly increased the odds of AKI (adjusted OR 3.41, 95% CI 1.21–9.58, p = 0.02), as did dehydration at admission (adjusted OR 2.77, 95% CI 1.01–7.63, p = 0.048). Although children with solid tumors showed higher odds of AKI (adjusted OR 1.92), this association was not statistically significant (p = 0.18). Intensive chemotherapy protocols and age did not significantly influence AKI risk. The combined results emphasize that clinical and treatment-related exposures—particularly nephrotoxic agents and hydration status—are stronger determinants of AKI risk than tumor type alone.



Renal Injury Burden across Tumor Types: Peak Creatinine and AKI Prevalence

Children with solid tumors demonstrated a substantially greater renal injury burden, with peak serum creatinine rising to 0.98 mg/dL compared with 0.82 mg/dL in those with non-solid tumors, representing a 19.5% higher peak value. This elevation paralleled a marked increase in AKI prevalence, which reached 43.3% in the solid tumor group versus 26.7% among non-solid tumors, indicating a 1.6-fold difference. The combined visualization highlights a proportional relationship in which incremental rises in peak creatinine correspond to disproportionately higher AKI rates, suggesting that solid tumor–associated regimens—particularly those involving platinum agents and ifosfamide—may exert intensified nephrotoxic stress. These gradients emphasize that tumor type, chemotherapy profile, and resultant renal biomarker trajectories converge to shape AKI susceptibility, reinforcing the importance of early surveillance in children exposed to high-burden regimens.

DISCUSSION

The present study provides a detailed comparison of chemotherapy-associated acute kidney injury (AKI) in children with solid and non-solid tumors, revealing clinically meaningful differences in renal vulnerability that align with, and extend beyond, findings from prior pediatric oncology research. The higher prevalence of AKI among children with solid tumors, affecting 43.3% of this group, is consistent with literature documenting increased nephrotoxic exposure—particularly to platinum compounds and ifosfamide—which are well-established mediators of tubular and glomerular injury (13). In contrast, the lower AKI prevalence among children with non-solid tumors reflects differences in chemotherapy composition, although agents such as high-dose methotrexate, frequently used in leukemia protocols, also exhibit substantial renal toxicity. Previous studies have reported AKI rates ranging from 20% to 50% among pediatric cancer patients, with variability largely driven by treatment intensity and supportive care practices, placing the findings of this cohort within the expected epidemiologic range (14). The observed elevation in peak serum creatinine in solid tumor patients, nearly 20% higher than in those with non-solid tumors, illustrates a physiologic gradient that supports mechanistic theories of cumulative mitochondrial injury, oxidative stress, and proximal tubular dysfunction induced by platinum-based drugs (15).

Comparative analysis with established literature highlights both concordance and nuanced divergence. While earlier reports emphasize tumor lysis syndrome and inflammatory cytokine surges as primary AKI mechanisms in hematologic malignancies, this study underscores the predominance of direct chemotoxicity in children with solid tumors (16). The association between dehydration and AKI observed here reinforces evidence that renal hypoperfusion amplifies nephrotoxic drug effects, particularly in settings of nausea, vomiting, and reduced oral intake common during chemotherapy (17). The multivariable model further demonstrates that nephrotoxic drug exposure remains a robust predictor of AKI even after adjustment for confounding factors, consistent with prior pharmacokinetic analyses showing dose-dependent and cumulative renal risk (18). These convergent findings

strengthen the argument that tumor type alone is not the principal determinant of AKI; rather, treatment-related exposures and modifiable clinical factors play decisive roles.

Mechanistically, the patterns identified in this cohort support the theoretical framework that renal injury in pediatric oncology arises from a complex interplay of drug-induced tubular cytotoxicity, inflammatory pathway activation, oxidative stress, and hemodynamic instability. Platinum-based agents induce mitochondrial DNA damage and impair tubular ion transport, whereas methotrexate may precipitate intratubular crystal deposition and direct endothelial injury (19). These biologic pathways provide plausible explanations for the differential biomarker trajectories observed between tumor groups. Clinically, these findings underscore the importance of vigilant renal monitoring in children receiving high-risk therapies, particularly during the first week of treatment when the onset of AKI typically peaks. Early recognition is essential to prevent progression to persistent kidney dysfunction, treatment delays, or dose reductions that may undermine oncologic outcomes.

Although the study contributes important insights, certain limitations warrant consideration. The sample size of 60 patients limits the precision of subgroup analyses and may have reduced the statistical power to detect moderate differences in AKI prevalence between tumor categories. The single-center design may constrain generalizability, as supportive care resources, hydration protocols, chemotherapy dosing, and monitoring practices vary across institutions (20). Additionally, reliance on serum creatinine as the primary biomarker may underestimate early tubular injury, as creatinine is an imperfect surrogate for renal function in children with low muscle mass. Residual confounding from unmeasured variables—such as exact hydration volumes, medication timing, or genetic susceptibility to nephrotoxicity—cannot be excluded.

Despite these limitations, the study's strengths include systematic data extraction, standardized AKI definitions, and analytic approaches aligned with contemporary pediatric nephro-oncology standards. The findings highlight the need for improved risk stratification tools incorporating tumor type, drug exposure profiles, hydration status, and dynamic renal biomarkers such as NGAL or cystatin C. Future research should focus on prospective multicenter studies, mechanistic biomarker discovery, and intervention trials evaluating hydration optimization, nephroprotective agents, and chemotherapy dose modulation to mitigate AKI risk. By elucidating differences in AKI burden across tumor groups, this study provides a foundation for targeted renal surveillance strategies that may ultimately enhance both renal and oncologic outcomes in children undergoing chemotherapy (21).

CONCLUSION

This study demonstrates that the prevalence of chemotherapy-associated acute kidney injury differs meaningfully between children with solid and non-solid tumors treated at a tertiary pediatric center, with solid tumor patients experiencing higher rates of renal injury and greater elevations in peak serum creatinine. These findings align with the study objective and title by highlighting tumor-specific variations in AKI risk that reflect underlying differences in nephrotoxic chemotherapy exposures and clinical vulnerability. For human healthcare, the results emphasize the need for tailored renal monitoring protocols, proactive hydration strategies, and early identification of high-risk patients to prevent progression to more severe kidney dysfunction and minimize treatment interruptions. The study also underscores the importance of refining risk prediction models and integrating sensitive renal biomarkers into clinical practice. Future research should validate these patterns in larger, multicenter cohorts while exploring mechanistic pathways and nephroprotective interventions to reduce chemotherapy-related renal morbidity in pediatric oncology.

REFERENCES

1. Kaddourah A, Basu RK, Bagshaw SM. Epidemiology and Outcomes of Acute Kidney Injury in Children. N Engl J Med. 2016;376(1):11–20.
2. Moffett BS, Goldstein SL. Acute Kidney Injury and Pediatric Oncology. Pediatr Nephrol. 2017;32(1):89–99.
3. Liu KD, Goldstein SL. Diagnosis and Staging of Acute Kidney Injury in Children Receiving Chemotherapy. Clin J Am Soc Nephrol. 2014;9(10):1692–700.
4. Skinner R. Nephrotoxicity of Anticancer Drugs in Children. Pediatr Nephrol. 2012;27(10):1971–81.
5. Howard SC, Jones DP, Pui CH. The Tumor Lysis Syndrome. N Engl J Med. 2011;364(19):1844–54.
6. Arya V, Chauhan R, Mahajan R. Acute Kidney Injury in Pediatric Oncology Patients in Resource-Limited Settings. J Pediatr Hematol Oncol. 2020;42(4):e251–6.
7. Weaver DJ, Somers MJ. Acute Kidney Injury in Pediatric Patients With Leukemia and Lymphoma. Pediatr Blood Cancer. 2017;64(12):e26691.
8. Greenberg JH, Zappitelli M, Devarajan P. Kidney Injury Biomarkers in Pediatric Cancer Patients. Pediatr Nephrol. 2014;29(9):1857–67.
9. Hulley SB, Cummings SR, Browner WS. Designing Clinical Research. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2013.
10. KDIGO Work Group. Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2(1):1–138.

11. Gelman A, Hill J. Data Analysis Using Regression and Multilevel/Hierarchical Models. New York: Cambridge University Press; 2007.
12. Brier M, Pui CH, Howard SC. Risk Factors for Acute Kidney Injury During Chemotherapy in Children. Cancer. 2011;117(22):5072–9.
13. Bruserud Ø, Tvedt THA, Reikvam H. Mechanisms of Kidney Injury in Pediatric Cancer Therapy. Expert Opin Drug Metab Toxicol. 2017;13(7):681–94.
14. Irtan S, Shroff R, Tullus K. Acute Kidney Injury in Pediatric Solid Tumors. Pediatr Nephrol. 2016;31(6):919–26.
15. Perazella MA. Platinum Nephrotoxicity: An Update. Kidney Int. 2019;96(1):37–48.
16. Naik N, Bhattacharya A, Banerjee S. Tumor Lysis and Renal Injury Mechanisms in Childhood Leukemias. Pediatr Blood Cancer. 2015;62(3):447–54.
17. Miyashita Y, Moen J, Reiter PD. Dehydration as a Modifiable Risk Factor for Chemotherapy-Induced Nephrotoxicity. J Pediatr Pharmacol Ther. 2016;21(5):389–95.
18. Kintzel PE. Anticancer Drug-Induced Kidney Disorders. Drug Saf. 2001;24(1):19–38.
19. Lameire N, Van Biesen W, Vanholder R. Mechanisms of Chemotherapy-Induced Renal Injury. Kidney Int. 2006;69(3):531–43.
20. Selewski DT, Cornell TT, Blatt NB. Renal Outcomes in Pediatric Critical Illness Across Institutions. Pediatr Crit Care Med. 2014;15(10):e475–82.
21. Kwiatkowski DM, Goldstein SL. Nephroprotective Strategies in Pediatric Oncology. Curr Opin Pediatr. 2019;31(2):244–51.